TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00591500

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
Study: NCT00727922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir
Description: Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
Study: NCT02225574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK-162
Description: Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
Study: NCT03356028

Intervention type: OTHER
Group type: OTHER
Intervention: salivary biological collection
Description: Saliva sampling will be done using a specific kit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: qualitative analysis of the discourse
Description: two semi-structured interviews, the first with the teenager alone, the second with the lone parents

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenthood
Description: Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive alterations
Description: Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Impact on schooling
Description: collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep disorders and associated somatizations
Description: Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
Study: NCT04561856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Perineural 4mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 2ml
Study: NCT02756403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200 mg
Study: NCT01421121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200 U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U EV71 vaccine with adjuvant
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200U EV71 vaccine without adjuvant
Description: inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml placebo, two doses, 28 days interval
Study: NCT02691741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL
Description: Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA® tri IOL
Description: Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study: NCT03531801

Intervention type: OTHER
Intervention: Pressure algometry and mapping referred pain areas
Description: The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.

Intervention type: OTHER
Intervention: Pressure algometry and mapping referred pain areas
Description: The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
Study: NCT05897918

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid 500 MG
Description: Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
Study: NCT01393184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab and Radiotherapy
Description: Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and Radiotherapy
Description: Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
Study: NCT01933464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Study: NCT03983928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT03586245

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferric pyrophosphate
Description: 57 Iron isotopically labeled FePP powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Description: 58 Iron isotope intrinsically labeled Aspergillus oryzae.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous sulfate
Description: 57 Iron isotopically labeled FeSO4 powder.
Study: NCT02756403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
Study: NCT00094887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
Study: NCT03101410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten
Description: Selected participants will be randomly allocated to treatment group (gluten or gluten free).
Study: NCT01205503

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
Study: NCT00094887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas will be delivered in the same manor as the experimental drug.
Study: NCT01205503

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline (used as a placebo) infused over the same time as mesna intervention

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline (used as a placebo) infused over the same time as mesna intervention
Study: NCT03101410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten free
Description: Selected participants will be randomly allocated to treatment group (gluten or gluten free).
Study: NCT03078634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-disciplinary clinic model
Description: Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard outpatient care
Description: Standard care provided in outpatient clinics staffed by GI doctors only
Study: NCT01760109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin Sodium and Sulbactam Sodium
Description: 1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
Study: NCT01205503

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
Study: NCT03152123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Pitolisant 40 mg or 240 mg (tablets over-capsuled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Pitolisant 40 mg or 240 mg (tablets over-capsuled)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: tablets over-capsuled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Phentermine 60 mg (capsule over-capsuled)
Study: NCT03362268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole
Description: 40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
Study: NCT04306718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: membrane peeling
Description: ERM and ILM are peeled routinely during surgery
Study: NCT00668863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Description: FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT02995655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-01
Description: CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Description: -Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
Study: NCT04098705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Introduction of the World Health Organization Triage Scale
Description: The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol.
Study: NCT02995655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
Study: NCT01933464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01316263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study: NCT04325776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Injection
Description: Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
Study: NCT03544268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Angiography
Description: Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT03544268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT04240691

Intervention type: BEHAVIORAL
Intervention: 60-Minutes-For-Health
Description: Refer to description under Groups

Intervention type: OTHER
Intervention: Time-and-Attention Control Session
Description: Refer to description under Groups
Study: NCT04214730

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NK combined with Chemotherapy
Description: Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will only receive Chemotherapy.
Study: NCT02834234

Intervention type: GENETIC
Intervention: comparative genomic analysis
Description: DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
Study: NCT02483429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRT Care
Description: The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
Study: NCT04427917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: PF-06835919 300 mg repeated doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo repeated doses
Study: NCT02863367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib：500 mg，po，qd, d1-14, every 3 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
Study: NCT01144234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Invitation letter for male spouse
Description: In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information letter
Description: In this arm the pregnant women got an information letter
Study: NCT02632500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of chest compressions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of chest compressions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of chest compressions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of chest compressions